Modeling the USA Winter 2021 CoVID-19 Resurgence

Genghmun Eng

doi:10.1101/2022.01.06.22268868

Abstract

The current USA 2021 CoVID-19 Winter Resurgence is modeled here with the same function used for analyzing prior USA CoVID-19 waves: Here, N(t) gives the total number of CoVID-19 cases above the previous baseline, and t_R sets the initial t_dbl = t_R (ln 2) pandemic t_dbl doubling time. Larger α_S values indicate that uninfected people are improving their pandemic mitigation efforts, such as Social Distancing and vaccinations ; while δ₀ > 0 accelerates the post-peak tail-off, and is empirically associated with mask-wearing. The pandemic wave end is when N(t) no longer increases.

The USA Summer 2021 resurgence results from our prior medrxiv.org preprints^* were used as a baseline. By 11/15/2021, an additional cases above baseline were found, signaling the USA Winter 2021 resurgence. This CoVID-19 wave is still in its initial stages. Presently, our analysis indicates that this CoVID-19 wave can infect virtually all susceptible persons; just like the initial stage of the USA Summer 2021 resurgence. Data up through 12/30/2021 gives these paremeter values: These values are identical to the prior 2020 USA Winter Resurgence results. Also, the and the values are similar. However, while the Winter 2020 Resurgence showed a significant mask-wearing effect , this initial USA Winter 2021 Resurgence shows practically no mask-wearing effects . If mask-wearing were to quickly rise to the Winter 2020 levels, it would give these projected totals: More robust mask-wearing and enhanced Social Distancing measures could further reduce these values (with 3 Figures).

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data used here is publicly available from the bing.com CoVID-19 Tracker Website.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.